NEW YORK, Dec. 11 - Atugen of Berlin said Tuesday it had signed a deal to validate gene targets for Oxford GlycoSciences.
Under the terms of the deal, OGS of Oxford, UK, will provide targets to Atugen, which will validate them using its animal models.
Atugen has developed a technology called GeneBloc, which is designed to block protein production, enabling the company to determine gene function.
The deal marks Atugen's fifth collaboration deal this year. The company’s custormers include Astra Zeneca, Axys Pharmaceuticals, Bayer, Roche BioScience, and Boehringer Ingelheim.
Financial terms of the deal with OGS were not disclosed.